Table 1.

Model inputs.

Parameter	Base case	Range		Distribution	Source
		Low	High
Treatment cost ($)
Camrelizumab per cycle	452.08	361.66	542.50	Gamma	Local market
Carboplatin per cycle	17.65	14.12	21.18	Gamma	Local market
Pemetrexed per cycle	1,103.30	882.64	1,323.96	Gamma	Local market
Docetaxel per cycle	94.10	75.28	112.92	Gamma	Local market
Gefitinib per cycle	161.47	129.18	193.76	Gamma	Local market
Bevacizumab per cycle	1,788.42	1,430.73	2,146.10	Gamma	Local market
Nivolumab per cycle	4,283.44	3,426.75	5,140.13	Gamma	Local market
Supportive care per cycle	338.00	270.40	405.60	Gamma	(15)
Routine follow-up per cyclea	85.71	68.57	102.85	Gamma	(15)
Palliative care per event	2,464.50	1,971.60	2,957.40	Gamma	(15)
Cost of managing adverse events ($)
Neutrophil count decreased	175.37	140.30	210.44	Gamma	(16)
Anemia	101.02	80.82	121.22	Gamma	(17)
Platelet count decreased	603.79	483.03	724.55	Gamma	(18)
Risk of adverse events in
camrelizumab group (grade III–IV)
Neutrophil count decreased	0.38	0.34	0.42	Beta	(7)
Anemia	0.19	0.17	0.21	Beta	(7)
Platelet count decreased	0.17	0.15	0.19	Beta	(7)
Risk of adverse events in
chemotherapy group (grade III–IV)
Neutrophil count decreased	0.30	0.27	0.33	Beta	(7)
Anemia	0.11	0.10	0.12	Beta	(7)
Platelet count decreased	0.12	0.11	0.13	Beta	(7)
Health utility
Stable disease	0.81	0.73	0.90	Beta	(19)
Disease progression	0.58	0.52	0.64	Beta	(20)
Health disutility
Neutrophil count decreased	0.20	0.18	0.22	Beta	(21)
Anemia	0.07	0.07	0.08	Beta	(21)
Platelet count decreased	0.11	0.10	0.12	Beta	(22)
Discount rate	0.05	0.00	0.08	Fixed in PSA	—

PSA, probabilistic sensitivity analysis.

^aThe cost of routine follow-up included the cost of outpatient physician visit, hospitalization, and laboratory tests.